Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1998-8-31
|
pubmed:abstractText |
The K-ras gene is mutated in > or =75% of human pancreatic adenocarcinomas and in a number of hyperplastic ductal lesions from noncarcinoma patients. In this study, the incidence of K-ras mutation was determined in a spectrum of focal proliferative pancreatic lesions to evaluate their preneoplastic significance. PCR-based mutation-enriched RFLP analysis was used to identify mutations in codon 12. Immunostaining for Ki67 and p53 was also performed. Forty-seven % of intraductal nonpapillary hyperplasias (8 of 17) contained codon 12 mutations, as did 55% of adenomatoid hyperplasias (6 of 11). This rate increased to 61% in papillary hyperplasias (27 of 44) and to 78% when there was severe dysplasia (7 of 9). The fraction of cells staining for the Ki67 proliferation marker showed a general correlation with the rate of K-ras mutation. Nuclear staining for p53 protein was seen only in two ductal lesions with severe dysplasia. No mutations were found in normal acinar tissue (n = 38), squamous metaplasia (n = 13), ductal complexes (n = 8), or focal acinar cell dysplasia (n = 5). There seemed to be a general correlation of proliferative potential with the presence of K-ras mutation in ductal lesions. However, because of the high prevalence of lesions with K-ras mutations, we conclude that this mutation alone cannot be taken as proof of significant risk for progression to carcinoma. Efforts to use the presence of K-ras mutations in DNA harvested from pancreatic juice or duodenal aspirates as an approach for diagnosis of occult pancreatic carcinoma seem vulnerable to a high false-positive rate.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1055-9965
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
515-21
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9641496-Adenocarcinoma,
pubmed-meshheading:9641496-DNA Primers,
pubmed-meshheading:9641496-Genes, ras,
pubmed-meshheading:9641496-Humans,
pubmed-meshheading:9641496-Immunohistochemistry,
pubmed-meshheading:9641496-Mutation,
pubmed-meshheading:9641496-Pancreatic Diseases,
pubmed-meshheading:9641496-Pancreatic Neoplasms,
pubmed-meshheading:9641496-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:9641496-Predictive Value of Tests,
pubmed-meshheading:9641496-Tumor Markers, Biological
|
pubmed:year |
1998
|
pubmed:articleTitle |
K-ras mutation in focal proliferative lesions of human pancreas.
|
pubmed:affiliation |
Department of Pathology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|